The osteoclast: A potential therapeutic target of bone and joint destruction in rheumatoid arthritis

Modern Rheumatology

Volumn 11, Issue 3, 2001, Pages 177-183

  Tanaka, S ^a   Nakamura, K ^a   Oda, H ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Adenovirus; C terminus Src family kinase (Csk); Osteoclast recepter activator of NF B ligand (RANKL); Src

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN TYROSINE KINASE;

ANIMAL CELL; BONE CELL; BONE DESTRUCTION; BONE METABOLISM; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; CYTOLOGY; ENZYME ACTIVITY; EVIDENCE BASED MEDICINE; GENE TARGETING; GENE THERAPY; JOINT DESTRUCTION; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; THERAPY;

EID: 0034752961     PISSN: 14397595     EISSN: None     Source Type: Journal    
DOI: 10.3109/s101650170001     Document Type: Review

References (37)

1. Modulation of osteoclast differentiation
2. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors?
3. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint
4. Osteoclast-like cells in murine collagen-induced arthritis
5. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis
6. A new mechanism of bone destruction in rheumatoid arthritis: Synovial fibroblasts induce osteoclastogenesis
7. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis
8. Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis
9. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families
10. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
11. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
12. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts
13. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts
14. Osteoprotegerin ligand: A common link between osteoclastogenesis, lymph node formation and lymphocyte development
15. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling
16. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice
17. Osteoprotegerin-deficient mice develop early-onset osteoporosis and arterial calcification
18. Expression of osteoclast differentiation factor in rheumatoid arthritis
19. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor
20. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma
21. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
22. Clinical trials in the gene therapy of arthritis
23. The promise of a new clinical trial - Intra-articular IL-1 receptor antagonist
24. c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption
25. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation
26. Modulation of osteoclast function by adenovirus vector-induced epidermal growth factor receptor
27. Targeted disruption of the c-src protooncogene leads to osteopetrosis in mice
28. Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts
29. Osteoclasts express high levels of p60c-src, preferentially on ruffled border membranes
30. Osteoclasts express high levels of pp60c-src in association with intracellular membranes
31. Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity
32. Herbimycin A, a pp60c-src tyrosine kinase inhibitor, inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo
33. In vitro and in vivo suppression of osteoclast function by adenovirus vector-induced csk gene
34. Use of an in vivo model to determine the effects of interleukin-1 on cells at different stages in the osteoclast lineage
35. Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts
36. Aminobisphosphonate (YM175) inhibits bone destruction in rat adjuvant arthritis
37. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial